statement

After the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.

A statement by 瑞銀. Statements are as reported by the cited publishers — not verified by DecisionGateway.

私有化完成後,泰格醫藥擬收購中國內地非目標業務,初步估值約2.055億美元;生物分析及藥物代謝動力學(DMPK)等目標業務將出售予Charles River Laboratories,初步估值約4.7億美元;方達控股創辦人李松及相關信託或收購海外非目標業務,初步估值約8440萬美元。
stockintelligencenewsPublished 2026-11-11 Read source

Discussion

0/2000

Related claims

More claims by 瑞銀

All claims by 瑞銀